Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Eratrectinib (VC004) in Healthy Subjects
NCT05528120Phase 1Completed
- Sponsor
- Jiangsu Vcare PharmaTech Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eratrectinib in NTRK fusion-positive solid tumor (2 arms), sponsored by Jiangsu Vcare PharmaTech Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Peak Time and 1 more. Started Oct 2022; status: completed.
02
Drugs
eratrectinib
03
Conditions
NTRK fusion-positive solid tumor
Beyond the preview
Go deeper on NCT05528120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528120.